Hourmant M, Bignon J D, Cesbron A, Soulillou J P
Service de Néphrologie et d'Immunologie Clinique, Centre Hospitalo-Universitaire, Nantes, France.
Clin Transpl. 1990:301-9.
Circulating antibodies reacting with donor lymphocytes, increasingly found in patients awaiting a kidney graft, are a cause of transplantation delays. Some of these antibodies may not be detrimental to the graft, and their recognition could be beneficial for the treatment of immunized patients. In this chapter, we report on a prospective study of 138 cases of kidney transplantation performed against a positive crossmatch (CM) on donor B lymphocytes. In all cases, a negative reaction was required on donor T lymphocytes using recipient pregraft sera. Sera of 36.3% and 43.6% of first and second-graft recipients, respectively, were also reactive on unseparated donor total lymphocytes. First grafts performed against donor B lymphocytes reacted like those with a negative CM in terms of graft survival, rejection incidence, and graft function in the first year. Surprisingly, an uncommonly high rate of success was observed in second grafts performed against a positive donor B-lymphocyte CM as compared to those with a negative B-cell CM (93.5% vs 62.8% graft survival at 2 years; p less than 0.05). In addition, these patients had a decreased rejection incidence and significantly better graft function (p less than 0.05) as compared to those grafted with a negative B-lymphocyte CM. In the 43.6% who also had a positive CM on total donor lymphocytes (negative CM on donor T cells) and would not have been grafted according to common CM policy, actuarial graft survival was 86.7%. Our results within the given procedure show that transplantation against a positive donor B-cell CM is not detrimental to a first graft.(ABSTRACT TRUNCATED AT 250 WORDS)
在等待肾移植的患者中越来越多地发现,与供体淋巴细胞发生反应的循环抗体是导致移植延迟的一个原因。其中一些抗体可能对移植物无害,识别这些抗体可能有利于免疫患者的治疗。在本章中,我们报告了一项针对138例供体B淋巴细胞交叉配型(CM)阳性的肾移植病例的前瞻性研究。在所有病例中,使用受者移植前血清时,供体T淋巴细胞需呈阴性反应。分别有36.3%的首次移植受者和43.6%的二次移植受者的血清对未分离的供体总淋巴细胞也有反应。就移植物存活、排斥发生率和第一年的移植物功能而言,针对供体B淋巴细胞进行的首次移植与CM阴性的移植反应相似。令人惊讶的是,与B细胞CM阴性的移植相比,针对供体B淋巴细胞CM阳性进行的二次移植成功率异常高(2年时移植物存活率分别为93.5%和62.8%;p<0.05)。此外,与B淋巴细胞CM阴性的移植患者相比,这些患者的排斥发生率降低,移植物功能明显更好(p<0.05)。在43.6%的供体总淋巴细胞CM也呈阳性(供体T细胞CM阴性)且按照常规CM策略本不应进行移植的患者中,精算移植物存活率为86.7%。我们在给定程序内的结果表明,针对供体B细胞CM阳性进行移植对首次移植并无损害。(摘要截断于250字)